TAR DNA binding proteinGenealiases: ALS10 · TDP-43
Q-omics provides the consensus-scored TARDBP profile across patient tissues and cancer cell-line models. TARDBP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TARDBP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TARDBP protein abundance shows 32,501 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where TARDBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TARDBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TARDBP survival associations across molecular data types. TARDBP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TARDBP RNA expression–survival associations across cancer types. High TARDBP expression shows unfavorable associations in ACC, LIHC, LGG, SARC and KIRP, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TARDBP RNA expression.
This table summarizes TARDBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TARDBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TARDBP shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, LIHC and LUSC. The HNSC box plot shows higher TARDBP RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with TARDBP in patient tissues and cancer cell lines. In patient samples, TARDBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TARDBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
